8.21
+0.09(+1.11%)
Currency In USD
| Previous Close | 8.12 |
| Open | 8.31 |
| Day High | 8.55 |
| Day Low | 8 |
| 52-Week High | 21.95 |
| 52-Week Low | 4.85 |
| Volume | 17,220 |
| Average Volume | 31,184 |
| Market Cap | 33.21M |
| PE | -0.64 |
| EPS | -12.85 |
| Moving Average 50 Days | 10.43 |
| Moving Average 200 Days | 9.09 |
| Change | 0.09 |
If you invested $1000 in FibroGen, Inc. (FGEN) 10 years ago, it would be worth $10.81 as of December 04, 2025 at a share price of $8.21. Whereas If you bought $1000 worth of FibroGen, Inc. (FGEN) shares 5 years ago, it would be worth $7.87 as of December 04, 2025 at a share price of $8.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
GlobeNewswire Inc.
Dec 02, 2025 9:05 PM GMT
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Than
FibroGen to Report Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 03, 2025 9:02 PM GMT
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
GlobeNewswire Inc.
Sep 24, 2025 11:00 AM GMT
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 tr